Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [Graphic News] More Koreans say they plan long-distance trips this year

    [Graphic News] More Koreans say they plan long-distance trips this year
  2. 7

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  3. 8

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  4. 9

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  5. 10

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
피터빈트

SK Chemicals submits Alzheimer’s medication to U.S. FDA

By 손지영

Published : April 3, 2016 - 18:12

    • Link copied

SK Chemicals, a pharmaceutical affiliate of South Korean conglomerate SK Group, on Sunday said it has submitted its patch-type Alzheimer’s drug SID710 to the U.S. Food and Drug Administration for approval.

SID710 is a generic drug referencing Novartis’ Exelon Patch (rivastigmine), a transdermal medication to treat dementia symptoms associated with Alzheimer’s disease.

SK Chemicals` patch-type Alzheimer`s medication S170 (SK Chemicals) SK Chemicals` patch-type Alzheimer`s medication S170 (SK Chemicals)

The Korean drug maker expects the FDA to grant approval in 2018. “We expect the drug to pass through all the review procedures without trouble,” a SK Chemicals spokesperson told The Korea Herald.

SK’s drug was already approved in the European Union in 2013. It currently sells the drug in 13 states in the region, including the U.K., France, Germany and Spain. SID710 takes up around 50 percent of the region’s Exelon Patch generics market, according to the firm.

If approved in the U.S., SID710 will take on the country’s transdermal Alzheimer’s medication market, which generated sales of around $618 million in 2015, according to market analyst IMS Health.

By Sohn Ji-young (jys@heraldcorp.com)

More from Headlines